Protein kinase Ce (PKCe) acts as an antiapoptotic protein and inhibits tumor necrosis factor-a (TNF)-related apoptosis-inducing ligand (TRAIL)-induced apoptosis in MCF-7 breast cancer cells. Members of the TNF receptor superfamily trigger apoptosis independent of the tumor suppressor protein p53, which primarily affects DNA damage-induced apoptosis. We have previously shown that PKCe acts upstream of Akt to inhibit receptor-initiated cell death. Since Akt can regulate p53, we have examined the involvement of p53 in PKCe-mediated TRAIL resistance. Overexpression of PKCe in MCF-7 cells (MCF-7/PKCe) caused a decrease in p53 and an increase in human homolog of murine double minute 2 (Hdm2) and phospho-Hdm2. Depletion of p53 by siRNA attenuated, whereas depletion of Hdm2 enhanced TRAIL-mediated apoptosis. Knockdown of Akt decreased Hdm2 phosphorylation, increased p53 level and potentiated TRAILinduced cell death. Depletion of PKCe from MCF-7 cells caused an increase in p53, whereas knockdown of p53 caused a decrease in Bid mRNA. Depletion of Akt from MCF-7/PKCe cells resulted in an increase in p53 and Bid. These results suggest that PKCe mediates TRAIL resistance by Akt-mediated phosphorylation of Hdm2 resulting in suppression of p53 expression and downregulation of Bid in MCF-7 breast cancer cells.
Introduction
The tumor suppressor protein p53 plays an important role in maintaining genomic integrity. In response to cellular stress, it can induce cell cycle arrest, apoptosis, DNA repair or senescence (Vogelstein et al., 2000) . The p53 gene is mutated in 50% of human cancers, and it is often inactivated in those cases in which p53 is not mutated (Vogelstein et al., 2000; Vousden and Lu, 2002) . p53 plays a key role in the intrinsic or mitochondrial cell death pathway (Schuler et al., 2000) . It functions as a sequence-specific transcription factor (Vogelstein et al., 2000) and increases the expression of proapoptotic Bcl-2 family members, including Bax, Bid, Noxa and Puma in response to DNA damage (Miyashita and Reed, 1995; Oda et al., 2000; Nakano and Vousden, 2001; Yu et al., 2001; Sax et al., 2002) . The extrinsic cell death pathway mediated via tumor necrosis factor-a (TNF) receptor superfamily signals apoptosis independent of p53 (Wang and El-Deiry, 2003; Kelley and Ashkenazi, 2004) . However, chemotherapeutic agents or radiation have been shown to induce death receptors, such as Fas, DR4 or DR5 in a p53-dependent manner (Owen-Schaub et al., 1995; Wu et al., 1997; Liu et al., 2004) .
The level of p53 is primarily regulated by the oncogene product murine double minute 2 (Mdm2), which acts as a ubiquitin ligase (Haupt et al., 1997; Kubbutat et al., 1997) . Mdm2 or its human homolog Hdm2 (human homolog of Mdm2) is a transcriptional target of p53 (Zauberman et al., 1993) , and once synthesized, it can inhibit the transcriptional activity of p53 (Oren, 1999) . It can also bind to p53 at the N-terminal domain leading to proteasome-mediated degradation of p53 (Chen et al., 1993; Haupt et al., 1997; Kubbutat et al., 1997; Oren, 1999) . Post-translational modification by phosphorylation is the major mechanism of p53 regulation (Oren, 1999) . p53 can be phosphorylated both at the N-and C-terminal domains by several different protein kinases (Toledo and Wahl, 2006) . In response to DNA damage, p53 becomes phosphorylated at multiple sites at the N terminus, and this prevents binding of Hdm2 to p53 causing stabilization of p53 (Kubbutat et al., 1997; Oren, 1999; Toledo and Wahl, 2006) . In contrast, phosphorylation of Hdm2 was shown to enhance Hdm2 activity and promote degradation of p53 (Zhou et al., 2001; Ogawara et al., 2002; Weber et al., 2005) . It has been shown that the oncogene product Akt/protein kinase B (PKB) phosphorylates Hdm2 at several sites, including Ser 166 and Ser 188 (Mayo and Donner, 2001; Zhou et al., 2001; Ogawara et al., 2002; Feng et al., 2004) . Phosphorylation of Hdm2 inhibits self-ubiquitination of Hdm2 and triggers its translocation to the nucleus where it can regulate p53 (Mayo and Donner, 2001; Zhou et al., 2001; Feng et al., 2004) .
Akt acts as an antiapoptotic protein and inhibits receptor-initiated apoptosis. It has been shown that TNF causes activation of Akt through phosphorylation at Ser 473 in murine fibrosarcoma WEHI-164 cells (O'toole et al., 2001) . We have shown that protein kinase Ce (PKCe), which also functions as an antiapoptotic protein, acts upstream of Akt to inhibit TNFinduced cell death in MCF-7 breast cancer cells (Lu et al., 2004 (Lu et al., , 2006 . However, the mechanism by which PKCe inhibits receptor-initiated apoptosis via Akt is not known. Although binding of death ligands to their receptors triggers extrinsic cell death pathway they can also engage mitochondrial or intrinsic cell death pathway via the proapoptotic Bcl-2 family member Bid in certain cell types (Gross et al., 1999; Eskes et al., 2000; Rudner et al., 2005) . We have recently shown that overexpression of PKCe in MCF-7 cells confers TNFrelated apoptosis-inducing ligand (TRAIL) resistance by causing upregulation of Bcl-2 and downregulation of Bid not only at the protein level but also at the mRNA level (Sivaprasad et al., 2007) . The mechanism by which PKCe downregulates Bid is not known. Since Bid is a transcriptional target of p53 (Sax et al., 2002) , we have examined if PKCe confers TRAIL resistance by regulating p53 via Akt. We provide direct evidence that PKCe regulates p53 expression via Akt/Hdm2 pathway. Additionally, a decrease in Bid by PKCe overexpression is mediated by p53. These results suggest that PKCe confers TRAIL resistance by Akt-mediated phosphorylation of Hdm2 resulting in suppression of p53 expression in MCF-7 breast cancer cells.
Results

Overexpression of PKCe downregulates p53 and confers TRAIL resistance
We have previously shown that PKCe mediates its antiapoptotic function via activation of Akt (Lu et al., 2006) although the mechanism by which Akt mediates antiapoptotic signaling by PKCe is not known. Since MCF-7 cells express wild-type p53 and it has been reported that Akt regulates p53 stability, we examined if overexpression of PKCe contributes to TRAIL resistance via downregulation of p53. We compared the levels of p53 in cells expressing an empty vector (MCF-7/Neo) or vector containing PKCe construct (MCF-7/PKCe). We have tested several stable clones of MCF-7 cells expressing PKCe and we have previously demonstrated that these clones exhibited resistance to TRAIL-induced cell death (Sivaprasad et al., 2007) . Figure 1 shows that overexpression of PKCe decreased p53 expression both at the mRNA ( Figure 1a ) and protein level (Figure 1b) . Unless otherwise mentioned, we have used clone 1 in all subsequent experiments and these cells are designated as MCF-7/PKCe. On the basis of densitometric scanning of four independent experiments there was a threefold decrease in p53 at the protein level in the MCF-7/PKCe cells ( Figure 1c ). To examine if downregulation of p53 was responsible for TRAIL resistance in MCF-7/PKCe cells, we depleted p53 using siRNA and examined the consequence of p53 knockdown on TRAIL sensitivity. We have monitored poly (ADP-ribose) polymerase (PARP) cleavage, which was shown to correspond to TRAIL-induced apoptosis in MCF-7 cells (Sivaprasad et al., 2007) . Figure 2 shows that knockdown of p53 ( Figure 2a ) attenuated TRAIL-induced PARP cleavage in both MCF-7/Neo and MCF-7/PKCe cells ( Figure 2b ). We also stained cells with Annexin V-Alexa 488 conjugate and propidium iodide (PI) to monitor apoptosis. Figure 2c shows that while treatment of MCF-7 cells with TRAIL resulted in 48% cell death, knockdown of p53-attenuated cell death to 24%. (Figure 3c ). To determine if the increase in Hdm2 in MCF-7/ PKCe cells was responsible for the decrease in p53, we depleted Hdm2 using siRNA and monitored p53 content. Figure 3d shows that knockdown of Hdm2 caused upregulation of p53 in both vector-transfected After 48 h, cell lysates were analysed by western blotting using the indicated antibodies. Glyceraldehyde-3-phosphate dehydrogenase (GAPDH) was used to control for loading differences. (d) Cells transfected with control of Akt siRNA were treated with or without 0.01 nM (MCF-7/Neo) or 0.1 nM (MCF-7/PKCe) TRAIL for the indicated times. Cell extracts were analysed by western blotting. GAPDH was used to control for loading differences.
Depletion of Akt caused downregulation of Hdm2, upregulation of p53 and enhanced TRAIL sensitivity To determine if overexpression of Hdm2 in MCF-7/ PKCe cells is mediated by Akt, we depleted Akt in both MCF-7/Neo and MCF-7/PKCe cells using siRNA. Figure 6a shows that knockdown of Akt decreased phosphorylation as well as level of total Hdm2 and increased p53 level (Figure 6b ). The effect of Akt knockdown on p53 level was more pronounced in PKCe-overexpressing cells compared to vector transfected cells, presumably because Akt pathway is activated by PKCe overexpression. Inhibition of Akt by dominant-negative Akt also caused an increase in p53 and a decrease in Hdm2 (Figure 6c ). Figure 6d shows that knockdown of Akt restored TRAIL sensitivity. Treatment of MCF-7/Neo cells with 0.01 nM TRAIL caused a time-dependent increase in PARP cleavage, whereas 0.1 nM TRAIL had little effect on PARP cleavage in MCF-7/PKCe cells. However, knockdown of Akt caused a substantial increase in PARP cleavage, especially in MCF-7/PKCe cells. Figure 7 shows that treatment of MCF-7/Neo and MCF-7/PKCe cells with 0.01 or 0.1 nM TRAIL, respectively, had little effect on cell death as determined by Annexin V/PI dyebinding assay. However, knockdown of either Akt or Hdm2 alone increased cell death and potentiated TRAIL-induced cell death. These results suggest that upregulation of Hdm2 or downregulation of p53 in MCF-7/PKCe cells was mediated by Akt, and knockdown of Akt and Hdm2 enhanced TRAIL sensitivity.
Knockdown of PKCe upregulates p53 and knockdown of p53 downregulates Bid
We have previously shown that knockdown of PKCe enhanced TRAIL-induced apoptosis (Sivaprasad et al., 2007) . Since overexpression of PKCe downregulates p53, we examined the consequence of PKCe knockdown on p53 expression. Figure 8 shows that depletion of PKCe by siRNA enhanced p53 mRNA level (Figure 8a ). 
PKCe confers TRAIL resistance via downregulation of p53
E Shankar et al signaling molecules prior to p53, it is conceivable that it may require sustained knockdown of PKCe to demonstrate an increase in p53 at the protein level. Since inhibition/depletion of PKCe results in cell death, it was difficult to incubate cells with PKCe siRNA for a prolonged period. Since Bid is a transcriptional target of p53 and we have previously shown that Bid is decreased in PKCeexpressing cells at the mRNA level, we examined the effect of p53 knockdown on Bid expression in MCF-7 cells. Figure 9a shows that silencing of p53 by siRNA decreased Bid level. In addition, knockdown of p53 by siRNA decreased Bid mRNA by almost twofold (Figures 9b and c) . Thus, PKCe may cause transcriptional downregulation of proapoptotic Bid via p53.
To further establish the importance of p53 in the regulation of Bid via PKCe, we overexpressed PKCe in breast cancer HCC1806 cells that do not express p53 (Figure 10a ). Overexpression of PKCe had little effect on Bid in HCC1806 cells (Figure 10b ). These results suggest that PKCe regulates Bid expression via p53.
Knockdown of Akt upregulates p53 and Bid
Since PKCe acts upstream of Akt and Akt regulates p53, we examined if Akt is involved in PKCe-mediated regulation of p53 target Bid. Figure 11 shows that depletion of Akt resulted in an increase in p53 expression (Figures 11a and b) and this was associated with an increase in Bid (Figures 11c and d) . We could not detect an increase in Bid protein, presumably because an increase in Bid induces apoptosis resulting in its own cleavage. This is consistent with the previous report where the authors showed that p53 transcriptionally regulates Bid but failed to observe an increase in Bid protein (Sax et al., 2002) . Thus, PKCe regulates Bid expression via Akt.
Discussion
The involvement of p53 in DNA damage-induced apoptosis is well established. The results of our present Glyceraldehyde-3-phosphate dehydrogenase (GAPDH) was used to control for loading differences.
PKCe confers TRAIL resistance via downregulation of p53 E Shankar et al study demonstrate that p53 can also play an important role during receptor-initiated apoptosis in MCF-7 cells. We have shown that one of the mechanisms by which the antiapoptotic protein PKCe evades TRAIL-induced apoptosis involves downregulation of p53. In addition, PKCe cooperates with another pro-survival protein Akt/PKB to mediate its effect on p53 downregulation and apoptosis. Furthermore, PKCe downregulates Bid via p53. The level of p53 is usually very low in normal cells but it is induced in response to DNA damage or cellular stress (Vogelstein et al., 2000) . MCF-7 breast cancer cells contain detectable amount of wild-type p53 under unstimulated conditions. The level of p53 is kept in check primarily by its transcriptional target Mdm2 via an autoregulatory feedback loop (Chen et al., 1993; Haupt et al., 1997; Kubbutat et al., 1997; Oren, 1999) . Since Akt is an important regulator of Mdm2, the status of Akt will also determine the level of p53. We have previously shown that PKCe enhanced both constitutive and TNF-induced phosphorylation and activation of Akt in MCF-7 cells (Lu et al., 2006) . In addition, Akt phosphorylation was attenuated when PKCe was depleted using siRNA (Lu et al., 2006) . Furthermore, knockdown of Akt abolished the antiapopotic effect of PKCe (Lu et al., 2006) . These results suggest that PKCe triggers antiapoptotic signal via Akt. However, the mechanism by which PKCe inhibits apoptosis through Akt was not known. Akt has been shown to phosphorylate and stabilize Hdm2 (Mayo and Donner, 2001; Zhou et al., 2001; Ogawara et al., 2002; Feng et al., 2004) . In the present study, we have shown that the increase in Akt phosphorylation in PKCe-overexpressing cells was associated with an increase in Hdm2 expression and phosphorylation. Furthermore, both mRNA and protein levels of p53 were decreased in PKCe-overexpressing cells, suggesting that activation of Hdm2 in MCF-7/PKCe cells may be responsible for p53 degradation. Since there is a negative feedback loop between p53 and Hdm2, a decrease in p53 can result in transcriptional activation of Hdm2 that may become further phosphorylated by Akt. While knockdown of p53 decreased TRAIL-induced apoptosis in MCF-7/ Neo and MCF-7/PKCe cells, knockdown of Hdm2 increased p53 level and enhanced TRAIL sensitivity in MCF-7/PKCe cells. Finally, knockdown of Akt decreased phosphorylation of Hdm2, enhanced p53 level and restored TRAIL sensitivity in MCF-7/PKCe cells. These results demonstrate the functional significance of Akt/Hdm2/p53 pathway in PKCe-mediated TRAIL resistance. While we focused on Hdm2 in our study, Akt phosphorylates a variety of targets, including Bad, glycogen synthase kinase 3b (GSK3b) and FOXO (Cross et al., 1995; Datta et al., 1997; Brunet et al., 1999) . Recently, it has been shown that treatment of MCF-7 cells with doxorubicin increased phosphorylation of Akt substrates FOXO3A, Bim and GSK3b and this was associated with inhibition of apoptosis (Li et al., 2007) . Thus, we cannot rule out the possible involvement of these targets of Akt in mediating TRAIL resistance. In addition, other factors besides Akt may also participate in the antiapoptotic function of PKCe.
p53 has been shown to activate transcription of several genes that play important role in DNA damageinduced apoptosis (Vogelstein et al., 2000; Vousden and Lu, 2002; Rozan and El-Deiry, 2007) . In addition to inducing genes that drive apoptosis it can also repress the expression of genes that inhibit apoptosis (Vousden, 2006) . However, transcriptional activation or repression of these genes may depend on the cell type and apoptotic stimuli. Although p53 has been shown to trigger expression of TRAIL receptors, including DR4 and DR5 in response to chemotherapeutic agents (Wu et al., 1997; Liu et al., 2004) , we failed to observe any alteration in the expression of these receptors by PKCe overexpression (Sivaprasad et al., 2007) . Furthermore, silencing of PKCe had no effect on DR4 and DR5 expression (data not shown). Recently, it has been reported that caspase-8 is a transcriptional target of p53, and p53-mediated upregulation of caspase-8 by chemotherapeutic drugs enhanced TRAIL sensitivity (Ehrhardt et al., 2008) . Thus, the status of p53 may decide responsiveness of various tumors to TRAIL-induced apoptosis. The proapoptotic Bcl-2 family protein Bid plays an important role in linking the extrinsic and the intrinsic cell death pathway. We recently showed that overexpression of PKCe decreased Bid both at the mRNA and protein level and knockdown of Bid inhibited TRAIL-induced apoptosis (Sivaprasad et al., 2007) . Since Bid is a potential transcriptional target of p53 (Sax et al., 2002) ), ERK and phospho-ERK were purchased from Cell Signaling Technologies (Beverly, MA, USA). siRNA SMARTpool against Akt, Hdm2, p53 and non-targeting SMARTpool siRNA were obtained from Dharmacon (Lafayette, CO, USA). Horseradish peroxidase-conjugated goat anti-mouse and donkey anti-rabbit antibodies were obtained from Jackson ImmunoResearch (West Grove, PA, USA). Annexin V-Alexa 488 and PI were obtained from Molecular Probes (Eugene, OR, USA). The enhanced chemiluminescence detection kit was from Amersham (Arlington Heights, IL, USA). Adenoviral construct containing dominant-negative (DN)-Akt was a kind gift from Dr Santosh DeMello (University of Texas, Dallas).
Cell culture MCF-7 and HCC1806 cells were maintained in RPMI 1640 medium supplemented with 10% heat-inactivated fetal bovine serum and 2 mM glutamine, and kept in a humidified incubator at 37 1C with 95% air and 5% CO 2 . MCF-7/Neo and MCF-7/PKCe were generated as previously described (Basu et al., 2002) .
Knockdown of Akt, Hdm2 and p53 siRNA SMARTpool against Akt, Hdm2, p53 or nontargeting SMARTpool were introduced into MCF-7/Neo and MCF-7/PKCe cells using Lipofectamine 2000 (Invitrogen, Carlsbad, CA, USA) as previously described (Sivaprasad et al., 2007) . Briefly, cells were seeded 1 day before transfection. Twenty-four hour following siRNA transfection, RNA was isolated for reverse transcription (RT)-PCR analysis, and forty-eight hour following siRNA transfection cells were treated with TRAIL and processed for western blot analysis.
RT-PCR analysis
Total RNA was isolated using RNA STAT-60 from Tel-Test Inc. (Friendswood, TX, USA), as per the manufacturer's protocol, and subjected to reverse transcription reaction using Promega (Madison, WI, USA) reverse transcriptase enzyme (ImProm-II). PCR amplifications were performed using the following primers: p53, forward, 5 0 -GTTCCGAGAGCTGAA TGAGG-3 0 ; reverse, 5 0 -TCTGACTCAGGCCCTTCTGT-3 0 . Hdm2, forward, 5 0 -GCAGCCAAGAAGATGAA-3 0 ; reverse, 5 0 -CATACTGGGCAGGGCTTATT-3 0 . Bid, forward, 5 0 -GCATGTCAACAGCGTTCCTA-3 0 ; reverse, 5 0 -GGAACC TGCACAGTGGAAAT-3 0 . PKCe, forward, AATGTCCAG GTGCAATACTC; reverse, CACCATCAAAAACATTCCTT. Actin, forward, 5 0 -TACAATGAGCTGCGTGTGGCT-3 0 ; reverse, 5 0 -ATCCACATCTGCTGGAAGGTGGA-3 0 . Cycle conditions for all PCRs were set up for 40 cycles as follows: denaturation at 95 1C for 1 min, annealing at 55 1C for 1 min, extension at 72 1C for 1 min and final extension at 72 1C for 10 min. The products were resolved on a 1% agarose gel containing ethidium bromide.
Immunoblot analysis
Equivalent amounts of protein from total cellular extracts were electrophoresed by sodium dodecyl sulfate (SDS)-PAGE and transferred electrophoretically to poly(vinylidene difluoride) membrane. Immunoblot analyses were performed as described before (Basu and Akkaraju, 1999) .
Annexin V/PI-binding assay Cells were treated with or without TRAIL for the indicated times. At the end of the incubation, both detached and attached cells were collected and washed with phosphatebuffered saline. Cells were then stained with Annexin V-Alexa 488 conjugate and PI according to the manufacturer's protocol and analysed using a flow cytometer (Coulter Epics, Beckman Coulter, Fullteron, CA, USA).
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